RAmylyx Pharma Q2 EPS $(0.39) Misses $(0.36) Estimate, Cash & Equivalents $279.8M. Cash runway Expected To Fund Operations Till 2028

Benzinga Newsdesk www.benzinga.com Negative 77.1%

Neg 77.1% Neu 0% Pos 0%

Amylyx Pharma (NASDAQ:AMLX) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.36) by 8.33 percent. This is a 15.22 percent increase over losses of $(0.46) per share from the same period last year.